Videos

Tanya Siddiqi, MD, discusses how she sees acalabrutinib fitting into the treatment landscape for patients with chronic lymphocytic leukemia following the results from the phase III ASCEND trial.

Relapsed ALK-Rearranged NSCLC

Simon J. Harrison, MD, gives key takeaways from his presentation on the ICARIA-MM study, which he recently presented at the 2019 International Myeloma Workshop.<br /> &nbsp;

Paul G. Richardson, MD, clinical program leader and director of clinical research of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and RJ Corman Professor of Medicine, Harvard School of Medicine, discusses the interesting safety and efficacy profiles of the HORIZON trial.

Prithviraj Bose, MD, discusses differences in the safety profiles of ruxolitinib and fedratinib in the treatment of myelofibrosis.

Kazuhiko Nakagawa, MD, PhD, discusses the role of EGFR tyrosine kinase inhibitors for the frontline treatment of patients with&nbsp;<em>EGFR</em>-positive non&ndash;small cell lung cancer.

Graft versus Host Disease

David S. Snyder, MD, discusses using ruxolitinib to prevent patients receiving stem cell transplantation from developing graft versus host disease.

Sarah Ferguson, MD, FRCSC, discusses her experience being involved in a population-based study of women with cervical cancer treated with a radical hysterectomy.

Kim N. Chi, MD, discusses the safety findings for the next-generation androgen receptor inhibitor apalutamide in combination with androgen deprivation therapy in patients with metastatic castration-sensitive prostate cancer, according to findings from the phase III TITAN study. This combination was compared with placebo and ADT and presented at the 2019 ASCO Annual Meeting.

Aditya Bardia, MBBS, MPH, discusses the value of liquid biopsies in the treatment landscape of breast cancer. The real value of liquid biopsy in this space lies in providing oncologists with insight on what&rsquo;s happening in tumor evolution.

Optimal Management of Relapsed/Refractory mHCC